Buy & Sell Banco Santander SA (SAN) – Banco Santander SA Price Today
Aura AI Summary
Key Stats
- $176.50BMarket Cap
- FinancialsSector
- -20.29%3M Drawdown
- -Enterprise Value
- 2.29%Dividend Yield
- 30% Buy | 70% SellTrading Activity
- 47 daysTypical Hold Time
Banco Santander SA (SAN) is currently valued at a market capitalization of $176.50B. Over the past 52 weeks, Banco Santander SA has traded between a low of $7.57 and a high of $13.21, highlighting its annual price range. Over the past three months, Banco Santander SA has recorded a drawdown of -20.29%, reflecting recent price volatility. Banco Santander SA offers a dividend yield of 2.29%, with the most recent dividend of $0.15 paid on 04 May 26. On average, investors hold Banco Santander SA for approximately 47 days, indicating typical investor behavior on the platform.
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Most Recent News
Rocket Lab shifts focus to space infrastructure, with Space Systems revenue surpassing Launch Services.
Rocket Lab is evolving from a launch service provider to a vertically integrated space and defense infrastructure company. Its Space Systems segment generated $136.7 million in quarterly revenue, overtaking its Launch Services segment and changing th...
WuXi Biologics named in 2026 Dow Jones Best-in-Class sustainability indices for top ESG performance.
WuXi Biologics has been recognized for its outstanding sustainability efforts by being included in the 2026 Dow Jones Best-in-Class World Index and Emerging Markets Index. This inclusion reflects the company's top 10% ranking globally in environmenta...
Geron reports Q1 revenue growth and updates on blood cancer drug progress.
Geron Corporation reported better-than-expected Q1 earnings with revenue of $51.84 million, up nearly 31% year-over-year. The company is focused on treating blood cancers, particularly lower-risk myelodysplastic syndromes (MDS), with its telomerase i...